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a  b  s  t  r  a  c  t
Ginkgo  biloba  (Gb)  is currently  the  most  investigated  and  adopted  herbal  remedy  for  cognitive  disorders
and  Alzheimer’s  disease  (AD).  Nevertheless,  its  efﬁcacy  in  the  prevention  and  treatment  of dementia  still
remains  controversial.  Speciﬁcally,  the added  effects  of Gb  in  subjects  already  receiving  “conventional”
anti-dementia  treatments  have  been  to date  very  scarcely  investigated.  We  evaluated  whether  the  use
of Gb is  associated  with  additional  cognitive  and functional  beneﬁt  in AD patients  already  in treatment
with  cholinesterase  inhibitors  (ChEIs).
Data are  from  mild  to moderate  AD patients  under  ChEI  treatment  recruited  in the  Impact  of Cholinergic
Treatment  USe  (ICTUS)  study.  Mixed  model  analyses  were  performed  to measure  six-monthly  modiﬁca-
tions in  the  Mini  Mental  State  Examination  (MMSE),  the  Alzheimer’s  Disease  Assessment  Scale-Cognitive
(ADAS-Cog)  subscale  score,  and  the  Activities  of  Daily  Living  (ADL)  scale  over  a follow-up  of  1  year
according  to the  additional  Gb  supplementation.
A total  of 828  subjects  were  considered  for the  present  analyses.  Signiﬁcantly  different  modiﬁcations
at  the  MMSE  score  over  the 12-month  follow-up  were  reported  between  patients  on  combined  therapy
compared  to those  only  taking  ChEIs.  On  the  contrary,  the  modiﬁcation  of the  ADAS-Cog  score between
the  two  groups  did  not  show  statistically  signiﬁcant  differences,  although  similar  trends  were  noticed.  No
signiﬁcant  modiﬁcations  of the  two  adopted  outcome  measures  were  observed  at the  mid-term  6-month
evaluation.  The  modiﬁcations  over  time  of  the ADL  score  did  not  show  statistically  signiﬁcant  differences
between  the  two groups  of interest.Our  ﬁndings  suggest  that  Gb  may  provide  some  added  cognitive  beneﬁts  in  AD patients  already  under
ChEIs  treatment.  The  clinical  m
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In the last decades, several natural products have been tested
or preventing the onset of dementia or delay its progression.
inkgo biloba (Gb) is currently the most investigated and adopted
erbal remedy for cognitive disorders and Alzheimer’s disease
AD) (Weinmann et al., 2010), and is listed as an anti-dementia
rug in the Anatomical Therapeutic Chemical Classiﬁcation system.
lausible mechanisms of its action against AD include antioxidant
nd antiapoptotic properties as well as potential inhibiting effects
gainst caspase-3 activation and amyloid- aggregation (Luo et al.,
002). Despite being widely used and tested, the efﬁcacy of Gb in
he prevention and treatment of dementia still remains contro-
ersial. Recently, two large randomized controlled trials (i.e. the
inkgo Evaluation of Memory (GEM) (DeKosky et al., 2008) and
he GuidAge (Vellas et al., 2012) studies) found no favorable effects
f Gb in primary prevention of dementia and AD in older individ-
als. In contrast, several studies have suggested that Gb is more
ffective than placebo in improving cognition in cohorts of patients
ith dementia (that is in secondary prevention) (Weinmann et al.,
010; Ihl, 2012). The few studies comparing the efﬁcacy of Gb
ersus cholinesterase inhibitors (ChEIs) in treating mild to moder-
te AD patients reported substantially comparable effects (Mazza
t al., 2006; Yancheva et al., 2009; Schulz, 2003; Wettstein, 2000).
owever, it is noteworthy the almost complete lack of studies
esting the added effects of Gb in subjects already receiving “con-
entional” anti-dementia treatments (e.g. ChEIs) (Weinmann et al.,
010; Yancheva et al., 2009).
In the present study, we hypothesize that Gb may  provide addi-
ional cognitive and/or functional beneﬁts in AD when combined
o “ﬁrst-line” treatments. The aim of these analyses is thus to eval-
ate the added effects of a Gb intervention in mild to moderate
D patients already in treatment with ChEIs. Therefore, we  mea-
ured the longitudinal modiﬁcations (occurred over a one-year
ollow-up) of the Mini Mental State Examination (MMSE) (Folstein
t al., 1975), of the Alzheimer’s Disease Assessment Scale-Cognitive
ADAS-Cog) subscale (Rosen et al., 1984), and of the Activities of
aily Living (ADL) scale (Katz et al., 1963) scores according to the
dditional Gb therapy in the Impact of Cholinergic Treatment USe
ICTUS) study.
ethods
tudy design and participants
The ICTUS study has been previously described elsewhere
Reynish et al., 2007; Canevelli et al., 2013). Brieﬂy, the ICTUS study
s a prospective multicenter cohort study aimed at evaluating the
linical course, treatment outcomes, and socioeconomic impact of
D in Europe. It involved 29 participating centers from 12 Euro-
ean countries, all members of the European Alzheimer Disease
onsortium (EADC), a network of clinical and research institutions
pecialized in the diagnosis and treatment of AD.
The following inclusion criteria were adopted in the ICTUS
tudy: (1) diagnosis of probable AD made according to National
nstitute of Neurological and Communicative Disorders and
troke-Alzheimer’s Disease and Related Disorders Association
NINCDS-ADRDA) criteria (McKhann et al., 1984); (2) MMSE
Folstein et al., 1975) score ranging from 10 to 26; (3) living in the
ommunity with a well-identiﬁed informal caregiver; (4) absence
f known conditions reducing to less than 2 years the patient’s
ife expectancy; (5) ability to sign an informed consent. The study
as approved by the Ethics Committee of the Toulouse University
ospital (coordinating center) and at individual centers by local
r national ethical committees. All the study participants signed
nformed consent.cine 21 (2014) 888–892 889
After the baseline assessment (between February 2003 and July
2005), participants were followed up for 2 years with mid-term re-
evaluations every 6 months. At baseline and at each follow-up visit,
a comprehensive clinical and neuropsychological assessment was
performed. In particular, the scales and questionnaires that were
administered to evaluate the neurological, functional, and social
factors of participants were the following: Clinical Dementia Rat-
ing (Morris, 1993), MMSE  (Folstein et al., 1975), ADAS-Cog (Rosen
et al., 1984), Zarit Burden Interview (ZBI) (Zarit et al., 1980), Neu-
ropsychiatric Inventory (NPI) (Cummings et al., 1994), ADL  (Katz
et al., 1963), and Instrumental Activities of Daily Living (IADL) scale
(Lawton and Brody, 1969). Moreover, at every visit, concomitant
pharmacological treatments were recorded.
For the present analyses, ICTUS participants were divided in two
groups: (1) AD patients receiving only ChEIs (i.e. donepezil, rivastig-
mine, and galantamine) at the baseline and 12-month follow-up
visits; and (2) AD patients receiving ChEIs and an additional Gb
supplementation at the baseline and 12-month follow-up visits.
All the patients on combined therapy were receiving the Gb extract
EGb761, at a daily dosage of 120 mg  in most of cases (56%). Partici-
pants not receiving ChEIs (e.g. in treatment with memantine) were
not considered as well as those changing group of treatment dur-
ing the considered follow-up. Such analytical approach allowed us
to mirror (although with the obvious limitations of a cohort study)
the design of a clinical trial (i.e., two groups exposed to different
treatments for the same length of time).
The present analyses were restricted to the ﬁrst 12 months in
order to avoid a potential selection bias. In fact, it is likely that
subjects taking Gb for a longer time are those who  have beneﬁciated
more from the therapy. Thus, extending the period of observation
may  have led to the selection of participants mainly presenting a
positive response to treatment.
Cognitive function tests
Modiﬁcations of the MMSE  and ADAS-Cog scores after 12
months of follow-up were considered as cognitive outcome vari-
ables of interest.
The MMSE  (Folstein et al., 1975) includes 30 items focused
at measuring different cognitive aspects (orientation, registration,
attention, recall, and language). The total score ranges from 0 to 30
with higher scores indicating better cognitive performance.
The ADAS-Cog (Rosen et al., 1984) represents the most widely
adopted cognitive outcome measure in AD trials. It includes eleven
items assessing different cognitive domains (memory, language,
and praxis). The total ADAS-Cog score ranges from 0 to 70, with
higher scores indicating greater cognitive impairment.
Functional ability tests
Modiﬁcations of the ADL scale scores after 12 months of follow-
up were considered as functional outcome variable of interest. The
IADL scale was not considered for the present analyses because
poorly reliable as functional measure in elderly men  (Fusco et al.,
2012).
The ADL scale (Katz et al., 1963) is a carer-applied questionnaire
ranking adequacy of performance in the 6 functions of bathing,
dressing, toileting, transferring, continence, and feeding. Patients
score 1 for independence in each of the 6 functions. Higher scores
indicate greater functional independence.
Other variablesThe following potential confounding factors were considered in
the present analyses: age, gender, educational level, income, and
their interaction with time.
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Table 1
Baseline characteristics of the cohort. Values are expressed as % or means ± SDs.
Total
(n = 828)
ChEIs
(n = 799)
ChEIs + Gb
(n = 29)
p
Age (years) 75.8 ± 7.8 75.8 ± 7.8 76.2 ± 6.8 0.74
Gender (women) 64.7 64.8 62.1 0.76
Education (years) 7.9 ± 4.6 7.8 ± 4.6 10.0 ± 4.9 0.01
BMI  (kg/m2) 25.3 ± 4.1 25.2 ± 4.0 26.0 ± 5.1 0.41
Hypertension 37.7 37.7 37.9 0.98
Diabetes 12.2 12.3 10.3 0.99
Ischemic heart diseases 12.6 12.5 13.8 0.78
Depression 24.3 24.0 31.0 0.39
Stroke 7.5 7.5 6.9 0.99
Falls  16.3 16.8 3.4 0.07
NPI  total score 11.9 ± 12.8 12.1± 13.0 8.2 ± 6.4 0.19
ZBI  20.7 ± 14.7 20.8 ± 14.7 17.8 ± 13.8 0.31
MMSE  20.5 ± 3.9 20.5 ± 3.9 21.2 ± 3.5 0.36
ADAS-Cog 20.4 ± 8.9 20.6 ± 8.9 15.8 ± 7.9 <0.001
ADL  5.5 ± 0.8 5.5 ± 0.9 5.8 ± 0.4 0.06
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tatistical analysis
In order to compare the baseline characteristics between the 2
reatment groups, we used 2 or Fisher’s exact (for expected values
5) test for categorical variables, Student test for quantitative vari-
bles with Gaussian (normal) distributions, and non-parametric
ests (Kruskal–Wallis test) for quantitative variables without nor-
al  distributions. In the absence of a normal distribution variables
ere transformed and tested on square root (for age, NPI and ZBI) or
ogarithmic values (BMI and ADAS-Cog) in order to obtain normal
istributions.
In order to compare changes over time for MMSE, ADAS-Cog,
nd ADL scores between the two patient groups: those receiving
hEIs alone and those treated by the combination ChEIs and Gb, lin-
ar mixed effect models with random intercept and random slope
ere used to take into account the heterogeneity of baseline scores
nd individual slopes over time. The term time2 was signiﬁcant,
howing that the MMSE, ADAS-Cog, and ADL slope are quadratic.
Two models were used either for MMSE, ADAS-Cog, and ADL.
he ﬁrst one was an unadjusted model. The second model was
djusted for: age, gender, education, income, and their interaction
ith time. In addition for the second model we used a linear mixed
odel with 3 levels in order to take into account the two  levels of
orrelation: between repeated observations of individual patients
nd between patients within country. The statistical package SAS
.3 software (SAS Institute Inc., Cary, NC) was used for the present
nalyses.
esults
Descriptive characteristics of the study sample at the baseline
ssessment are shown in Table 1. A total of 828 patients (women
4.7%) were considered for the present analyses. The sample popu-
ation had a mean age of 75.8 (SD 7.8) years. MMSE  and ADAS-Cog
cores at baseline were 20.5 (SD 3.9) and 20.4 (SD 8.9), respec-
ively, indicating a moderate cognitive decline. ADL score was  5.5
SD 0.8), indicating a minimal impairment of functional abilities. At
he baseline and 12-month visits, 799 participants (96.5%) were on
hEIs alone treatment, and 29 (3.5%) were on a combined therapy of
hEIs and Gb. At the baseline visit, donepezil was the most assumed
hEI (55%) followed by galantamine (27%) and rivastigmine (18%).
The two groups were comparable for age, gender, and co-
orbidities. Signiﬁcant differences between them were reported
or education (p = 0.01) and ADAS-Cog scores at baseline (p < 0.01).ily Living; ChEIs: cholinesterase inhibitors; Gb: Ginkgo biloba; MMSE: Mini Mental
In particular, participants on combined treatment were found to be
more educated and less cognitively impaired.
The different modiﬁcations of MMSE  and ADAS-Cog scores in the
two groups of interest are presented in Table 2. Signiﬁcant differ-
ent modiﬁcations at the MMSE  score over the 12-month follow-up
were reported between patients on combined therapy compared
to those only taking ChEIs (+1.86, SE 0.67; p = 0.006). These results
were conﬁrmed in the multivariate model after adjusting for poten-
tial confounders (+1.91, SE 0.67; p = 0.005). On the contrary, the
modiﬁcation of the ADAS-Cog score between the two groups did not
show statistically signiﬁcant differences, although similar trends
were noticed. Similarly, no signiﬁcant modiﬁcations of the two
adopted outcome measures were observed in secondary analy-
ses exploring cognitive function modiﬁcations at the mid-term
6-month assessment.
The modiﬁcations over time of the ADL score did not show sta-
tistically signiﬁcant differences between the two  groups of interest
(Table 3).
Discussion
In the present study, we explored modiﬁcations of cognitive and
functional performance over one year of follow-up in a large cohort
of mild to moderate AD patients treated with ChEIs, according to
the additional Gb use. A signiﬁcant difference of the MMSE  mod-
iﬁcations was  reported between participants using the combined
therapy compared to those only taking ChEI after one year of follow-
up. A similar, but not statistically signiﬁcant trend was found for
the ADAS-Cog modiﬁcations. Conversely, no differences in terms of
functional ability (i.e. ADL score modiﬁcations) were observed over
time between the two  groups of interest.
The clinical meaningfulness of our ﬁndings remains to be clar-
iﬁed. The cognitive beneﬁt observed among patients on combined
therapy (as measured by an increase of the MMSE score) was found
to be statistically signiﬁcant only at the 12-month, but not at the
6-month assessment. The partially positive results obtained for the
Gb at the end of the 12-month follow-up might be due to our study
design (analyses from a cohort study, and not from a randomized
controlled trial). The cohort study design does not allow us to surely
ascertain the period of exposure and adherence of participants to
the treatments of interest (i.e. subjects may  shift groups at any
time during the period of observation or irregularly assume the
treatments). For this reason, we  performed our analyses selecting
participants taking the same treatment during the ﬁrst 12-
month follow-up of ICTUS. However, we cannot not exclude that
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Table  2
Different evolutions of MMSE  and ADAS-Cog scores according to the two  groups of interest (baseline–follow-up). Values are expressed as means ± SEs (Standard Errors).
Results from linear mixed models.
Mean differences (follow-up − baseline) Mean difference of modiﬁcations between the two groups
Unadjusted Adjusted
MMSE  6 months
ChEIs −0.41 ± 0.10 +0.92 ± 0.55
p  = 0.10
+0.99 ± 0.56
p  = 0.08
ChEIs + Gb +0.51 ± 0.54
MMSE  12 months
ChEIs −1.44 ± 0.12 +1.86 ± 0.67
p  = 0.006
+1.91 ± 0.67
p  = 0.005
ChEIs + Gb +0.42 ± 0.66
ADAS-Cog 6 months
ChEIs +1.25 ± 0.20 −0.80 ± 1.11
p = 0.47
−1.03 ± 1.11
p = 0.35ChEIs + Gb +0.45 ± 1.09
ADAS-Cog 12 months
ChEIs +3.41 ± 0.25 −1.41 ± 1.36
p = 0.30
−1.49 ± 1.36
p = 0.27ChEIs + Gb +2.00 ± 1.33
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Adjusted for age, gender, education, income, and their interaction with time.
egative differences at the ADAS-Cog indicate improvement of cognitive function. 
DAS-Cog: Alzheimer Disease Assessment Scale-Cognitive subscale; ChEIs: choline
articipants perceiving an amelioration of their health status from
he Gb treatment were indeed those more likely to be included in
he group on combined therapy. On the other hand, those feeling
he combined therapy as unworthy probably quit the Gb treatment
fter a short time of trial (also considering the treatment costs),
hus were likely to be excluded from the present study analyses. As
 consequence, an overestimation of our ﬁndings, especially for the
2-month assessment, needs to be considered. Basing on the same
onsiderations, we also limited our analyses to 12 months, not
onsidering the cognitive and functional modiﬁcations occurred in
he second year of follow-up of the ICTUS cohort. In fact, it is likely
hat patients experiencing the greatest beneﬁt from the added Gb
herapy would have more probably completed the observation
eriod compared to participants reporting minor efﬁcacy. This
ay  have further increased the above-described selection bias.
Based on available evidence, Gb may  potentially represent an
interesting” add-on therapy in demented subjects already receiv-
ng “conventional” pharmacological treatments. In fact, it is well
olerated (Weinmann et al., 2010) and may  provide additional
eneﬁts by targeting different pathophysiological mechanisms.
o our knowledge, only one study had previously investigated
he cognitive efﬁcacy of a combined ChEIs + Gb treatment in AD
Yancheva et al., 2009). In this study, 96 AD outpatients were ran-
omly assigned to Gb (240 mg/day), donepezil (initially 5 mg/day,
hen 10 mg/day after 4 weeks), or to the combined treatment
same doses). After 22 weeks, no signiﬁcant differences concerning
able 3
ifferent evolutions of ADL scores according to the two  groups of interest (baseline–follo
ixed  models.
Mean differences (follow-up − baseline) 
ADL 6 months
ChEIs −0.16 ± 0.01 
ChEIs + Gb −0.19 ± 0.08
ADL 12 months
ChEIs −0.32 ± 0.03
ChEIs + Gb −0.38 ± 0.16
djusted for age, gender, education, income, and their interaction with time.
egative differences at the ADL indicate decline of functional abilities.
DL: Activities of Daily Living; ChEIs: cholinesterase inhibitors; Gb: Ginkgo biloba.e differences at the MMSE  indicate improvement of cognitive function.
e inhibitors; Gb: Ginkgo biloba; MMSE: Mini Mental State Examination.
cognitive, behavioral, and functional outcomes were noticed
between the three treatment groups. Interestingly, compared to
donepezil monotherapy, the adverse event rate was lower under
Gb treatment and even under the combination treatment. Nev-
ertheless, the small sample size did not allow any deﬁnitive
conclusion. Also, the use of cognitive measures (i.e. Syndrom Kurz
Test, Clock-Drawing Test, and Verbal Fluency Test) different from
those available in the ICTUS study does not allow a direct compar-
ison with our ﬁndings.
Our study has several strengths. The analyses were per-
formed in a large sample of AD patients, recruited at numerous
dementia clinics across several European countries. The modiﬁ-
cation of cognitive performance was  assessed through two widely
used outcome measures (i.e. the MMSE, and ADAS-Cog) aiming at
reducing observation bias. Moreover, the study design with semi-
annual clinical assessments provided a detailed monitoring of
cognitive changes. Nevertheless, some issues should be discussed
because potentially inﬂuencing our results. First, the observational
design did not allow us to conclude in terms of causality. In fact, the
two groups were signiﬁcantly different with regard to education
and ADAS-Cog scores at baseline, two  well-established factors asso-
ciated with the course of the disease, the performance at cognitive
testing, and the response to treatments. Thus, it may  be hypoth-
esized that patients on combined ChEIs + Gb therapy may  have
presented a more relevant cognitive beneﬁt because more edu-
cated and less cognitively impaired. So, even if these factors were
w-up). Values are expressed as means ± SEs (Standard Errors). Results from linear
Mean difference of modiﬁcations between the two groups
Unadjusted Adjusted
−0.03 ± 0.08
p = 0.74
−0.04 ± 0.08
p = 0.58
−0.05 ± 0.16
p = 0.74
−0.09 ± 0.16
p = 0.58
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roperly taken into account in the adjusted models, the consequent
ias might have not been completely erased. Moreover, despite
onsidering potential confounders, third factors may  have affected
r may  differently explain our ﬁndings. For example, the treatment
oses were not stable and uniform during the study, healthier
atients may  have easier access to the Gb treatment, and the
oncomitant use of other psychoactive drugs may  have interacted
ith the tested pharmacological interventions. The study design
nd available data also do not allow appreciating and adequately
aking into account the possible exposure to the Gb before the
CTUS baseline visit. For example, it is possible a residual effect of
reviously stopped Gb treatment in the ChEI group as well as an
verestimation of beneﬁts in participants having been taking the
ombined therapy for several years before. Finally, our analyses
ight have been affected by the low number of participants taking
b during the period of interest.
In conclusion, our ﬁndings suggest that the Gb might provide
ome added cognitive beneﬁts in AD patients already under ChEIs
reatment. However, the clinical relevance of such effects remains
o be conﬁrmed and clariﬁed in future ad hoc designed trials.
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